Life after prostate cancer diagnosis: protocol for a UK-wide patient-reported outcomes study by David H Brewster, Victoria Cairnduff, Eila Watson, Amy Downing, Adam W Glaser, Penny Wright, William Cross, Conan Donnelly, Anna Gavin, Carol Rivas, Richard Wagland, Peter Selby, Luke Hounsome, Therese Kearney, Rebecca Mottram, Majorie Allen, Oonagh McSorley, Hugh Butcher, Paul Kind, James W H Catto, Dyfed Huws, Emma McNair, Lauren Matheson, Johana Nayoan, Mike Horton, Jessica Corner, Julia Verne

“…The Life After Prostate Cancer Diagnosis (LAPCD) study is a UK-wide patient-reported outcomes study which will generate information to improve the health and well-being of men with prostate cancer.Methods and analysis Postal surveys will be sent to prostate cancer survivors (18–42 months postdiagnosis) in all 4 UK countries (n=∼70 000). …”
Get full text

Co-modulation of a circular form of PCDH11Y during neuroendocrine differentiation of prostate cancer by Giovanni Pecoraro, Ilaria Leone, Silvia Nuzzo, Santiago Negueruela, Giovanni Smaldone, Lorena Buono

Subjects: Get full text

Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients by Gati K. Panigrahi, Prakash P. Praharaj, Hiroki Kittaka, Asit R. Mridha, Olen M. Black, Rakesh Singh, Roger Mercer, Adrie van Bokhoven, Kathleen C. Torkko, Chapla Agarwal, Rajesh Agarwal, Zakaria Y. Abd Elmageed, Hariom Yadav, Santosh K. Mishra, Gagan Deep

Subjects: Get full text

Somatic Mitochondrial DNA Point Mutations Used as Biomarkers to Demonstrate Genomic Heterogeneity in Primary Prostate Cancer by Christian Arstad, Kristin Taskén, Paulo Refinetti, Ulrika Axcrona, Karl-Erik Giercksky, Per Olaf Ekstrøm

“…Prostate Cancer…”
Get full text

Focal therapy of prostate cancer: Use of artificial intelligence to define tumour volume and predict treatment outcomes by Wayne G. Brisbane, Alan M. Priester, Anissa V. Nguyen, Mark Topoozian, Sakina Mota, Merdie K. Delfin, Samantha Gonzalez, Kyla P. Grunden, Shannon Richardson, Shyam Natarajan, Leonard S. Marks

Subjects: Get full text

Corrigendum to “Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy” by Katherine Neubecker, Beverley Adams-Huet, Irfan M. Farukhi, Rosinda Castanon, Ugis Gruntmanis

Get full text

Enhancing prostate cancer segmentation in bpMRI: Integrating zonal awareness into attention-guided U-Net by Chao Wei, Zheng Liu, Yibo Zhang, Lianhui Fan

“…Purpose Prostate cancer (PCa) is the second most common cancer in males worldwide, requiring improvements in diagnostic imaging to identify and treat it at an early stage. …”
Get full text

The Direct Healthcare Expenditures of Prostate Cancer by Disease Severity: Evidence from US National Survey Data by Peter J. Mallow, Jie Chen, John A. Rizzo, John R. Penrod, Geralyn C. Trudel, Teresa M. Zyczynski

“…**Background:** In the United States, approximately 2.8 million men have a history of prostate cancer (PC). **Objective:** This study quantified the effects of PC, overall and by disease severity on direct healthcare costs to insurers and patients. …”
Get full text

The potential of Curcuma longa L. bioactive compounds as RSK inhibitors for the treatment of prostate cancer: in silico study by Olusola Olalekan Elekofehinti, Foluso Adeola Taiwo, Moses Orimoloye Akinjiyan, Ifeoluwa Rachael Adetoyi, Folasade Oluwatobiloba Ayodeji, Adedotun Olayemi Oluwatuyi, Oluwapelumi Nifesimi Akintoye, Idayat Oyinkansola Kehinde, Bolanle Esther Adedapo, Opeyemi Iwaloye

Subjects: Get full text

Prostate Cancer in a Male with Holt-Oram Syndrome: First Clinical Association of the TBX5 Mutation by Noel J. Aherne, Guhan Rangaswamy, Pierre Thirion

“…We report the first clinical case of prostate cancer in an individual with Holt Oram syndrome.…”
Get full text

Incidental Discovery of Hepatocellular Carcinoma on 18F-PSMA PET CT Performed for Prostate Cancer Reassessment by Lauren Hekman, Eva Napierkowski, Natalie C. Hartman, Jeffrey L. Ellis, Robert H. Wagner, Davide Bova, Maria M. Picken, Robert C. Flanigan

“…We describe the case of a 76-year-old male with a rising prostate-specific antigen (PSA) after definitive prostate cancer treatment and no prior liver pathology who was incidentally found to have HCC on 18F-PSMA PET.…”
Get full text

Retracted: Effect and Mechanism of lncRNA CERS6-AS1 on the Biological Behavior of Prostate Cancer Cell by Applied Bionics and Biomechanics

Get full text

Urologic Characteristics and Sexual Behaviors Associated with Prostate Cancer in an African-Caribbean Population in Barbados, West Indies by Anselm J. M. Hennis, Suh-Yuh Wu, Barbara Nemesure, M. Cristina Leske

“…Prostate Cancer…”
Get full text

A case of de novo neuroendocrine prostate cancer presented with elevated level of serum CEA carrying BRCA2 mutation: case report and literature review by Weizhe Han, Nihati Rexiati, Fang Yu, Yongzhi Wang, Yueli Tian, Jianyuan Wu, Gang Wang, Tao Liu, Zhonghua Yang

Subjects: “…neuroendocrine prostate cancer (NEPC)…”
Get full text

Comprehensive analysis of the interaction microbiome and prostate cancer: an initial exploration from multi-cohort metagenome and GWAS studies by Gui-Chen Ye, Hao Peng, Jia-Cheng Xiang, Ling-Tao Miao, Cheng-Zhi Liu, Shao-Gang Wang, Qi-Dong Xia

Subjects: “…Prostate cancer…”
Get full text

Potentials and Limitations of Real-Time Elastography for Prostate Cancer Detection: A Whole-Mount Step Section Analysis by Daniel Junker, Georg Schäfer, Friedrich Aigner, Peter Schullian, Leo Pallwein-Prettner, Jasmin Bektic, Wolfgang Horninger, Ethan J. Halpern, Ferdinand Frauscher

“…Objectives. To evaluate prostate cancer (PCa) detection rates of real-time elastography (RTE) in dependence of tumor size, tumor volume, localization and histological type. …”
Get full text

Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis by Mike Fang, Mary Nakazawa, Emmanuel S. Antonarakis, Chun Li

“…Prostate Cancer…”
Get full text

The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer by Ahmet Kiper, Orhan Yiğitbasi, Abdurrahim Imamoglu, Can Tuygun, Celaleddin Turan

“…The changes in serum prostate-specific antigen (PSA) concentrations can be used as a prognostic factor in patients undergoing maximum androgen blockage for metastatic prostate cancer. A total of 149 patients followed in our department were classified into 4 groups on the basis of PSA changes: group 1, those with normalisation of PSA levels within the first 3 months; group 2, those with normalisation of PSA between months 3 and 6; group 3, those with a decrease in PSA, but not reaching normal range; group 4, those with no decrease. …”
Get full text

Tegaserod maleate exerts anti-tumor effects on prostate cancer via repressing sonic hedgehog signaling pathway by Maoping Cai, Shengdong Ge, Yaying Hong, Yao Chen, Yang-Zi Ren, Dacai Zhong, Mingkun Chen, Yuan Liu, Zhe-Sheng Chen, Ninghan Feng, Zhanghui Chen, Shan-Chao Zhao

Subjects: “…Prostate cancer (PCa)…”
Get full text

Anticancer Drug-Induced Apoptosis and Cytotoxicity in Prostate Cancer Cells Are Modulated by Organ-Specific Stromal Cell Factors by Bal L. Lokeshwar, Kamalaveni R. Prabhakar, Tie Yan Shang, Zafiria Mourelatos, De-Quan Li

Get full text